Births affect breast cancer risk Read more...

Herceptin ‘cuts chance of breast cancer relapse’ Read more...

Researchers capture complexities of breast cancer tumours to improve treatment, diagnostics Read more...

Conversely, he adds, a high-risk result could alert the clinical oncologist that the patient may be likely to demonstrate early progression , and so look for an alternative management strategy. Related posts: … Read more...

Herceptin: Long-Term Benefits for Breast Cancer Read more...

FDA grants meeting on Avastin for breast cancer Read more...

Tools for improving the characterization and visualization of changes in neuro- oncology patients. … Tools for improving the characterization and visualization of changes in neuro- oncology patients Read more...

For those patients in the high-risk group, the result can alert the clinical oncologist to be ready for early progression and look for alternative management strategy, Dr Rosell said. Commenting on the research, which she was not … Read more...

In the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial, 302 men undergoing active surveillance were randomly assigned to receive either dutasteride, which belongs to the class of drugs known as 5-alpha reductase inhibitors, or placebo for 3 … The Genitourinary Cancers Symposium was cosponsored by the American Society of Clinical Oncology , the American Society for Radiation Oncology , and the Society of Urologic Oncology . … Read more...

THURSDAY, Feb. 24 (HealthDay News) — The cancer drug Herceptin produces significantly longer disease-free survival in women with an aggressive type of early-stage breast cancer who take the drug for a year after standard chemotherapy, a new study suggests. Read more...